#NYC #Faith #MayorAdams #Change

The post NYC Faith Office in forefront of change in NYC. appeared first on Good News!.

Denise Rich- Founder of Gabrielles Angels

Listen to “Gabrielles Children, Crane Club at 7pm (85 10th Ave, New York, NY 10011). The Young Angels Gala, sponsored by Cantor” on Spreaker.

Honoree – Kyle Lutnick serves as Executive Vice Chairman of Cantor Fitzgerald, L.P. and has been a Director of Newmark Group, Inc. since February 2025. Most recently Lutnick served as Global Managing Director of Knotel, Inc., Newmark’s flexible office and workspace business and prior was Knotel’s General Manager of UK & EMEA and Vice President of Business Development. Previously, Lutnick was a member of Newmark’s market-leading retail advisory team, where he advised clients in New York City, one of the most dynamic commercial markets in the world.  Lutnick graduated with a Bachelor of Arts in Psychology from Stanford University.

Listen to “Gabrielles Children, The Young Angels Gala, sponsored by Cantor” on Spreaker.

Honoree – Ms. Andrea DiNunzio.
With over 20 years in the beauty industry, Ms. DiNunzio has driven growth and profitability for Fortune 500 and Private Equity-backed companies including L’Oréal, Laura Mercier, and Neutrogena. Currently General Manager of Ultra-Luxury Skincare and Fragrance at Coty USA, she is accelerating the company’s skincare platform. Her previous leadership roles include President of Lashify, where she doubled sales in 12 months, CEO of Dermaflash, and General Manager of North America for Iluminage Beauty, where she led successful turnarounds. Her expertise spans strategic planning, P&L management, marketing, product development, customer insights, sales leadership, and building brands across DTC, Mass, Prestige, Social, and TV Retail channels. Known for cultivating high-performance teams and empowering next-gen leaders through organizations like CEW and Chief, she holds a BA in Biology, an MBA from the University of Virginia, and is a Pew Foundation genetics research grant recipient.

Listen to “Gabrielles Children, The Young Angels Gala, sponsored by Cantor” on Spreaker.

Oysters by East Hampton Oyster Shucker

Listen to “Gabrielles Children, The Young Angels Gala, sponsored by Cantor” on Spreaker.

Athenna Crosby, Ms. World America

BIANCA PETERS, FOX5 NEWS ANCHOR, TO HOST GABRIELLE’S ANGEL FOUNDATION’S YOUNG ANGELS GALA on June 23, 2025

Honorees include longtime supporter Kyle Lutnick, Executive Vice Chairman of Cantor Fitzgerald, L.P. and Andrea DiNunzio, General Manager of Ultra-Luxury Skincare and Fragrance of Coty USA

New York, NY (May 20, 2025) – Gabrielle’s Angel Foundation for Cancer Research announced today that Bianca Peters will host their upcoming Young Professionals Committee’s Young Angels Gala on June 23, 2025 at the Crane Club at 7pm (85 10th Ave, New York, NY 10011). The Young Angels Gala, sponsored by Cantor Fitzgerald, Tommy Bahama, LVH Global is an event born from the desire of young professionals to give back and make a difference in the fight against cancer. All proceeds from The Young Angels Gala will benefit Gabrielle’s Angel Foundation’s music therapy programs and cancer research.

Guests at the event will enjoy an evening of cocktails, connection, and impact in support of blood cancer research. Now in its 7th year, this dynamic event brings together New York’s emerging philanthropists, change makers, and industry leaders to continue the legacy of founder Denise Rich, who created the foundation in memory of her daughter Gabrielle, who lost her life to leukemia. The evening will feature music by DJ Chloe Jane along with other exciting surprises and notable guests. Tickets can be purchased at https://gabriellesangels.org/events-dates/ypc-gala/.

Other fun features at the event will include Oysters by East Hampton Oyster Shucker, a lil sweet treats candy cart underwritten by Double O Fragrance, live illustrations by artist Deanna First and celebrity magician and mentalist Josh Pele. Guests will be treated to cocktails and wines sponsored by Tito’s Handmade Vodka, Pernod Richard, The Macallan, LALO Tequila, Tres Chicon, Wolffer Estates, Hamptons Muse and Spring 44 Gin.

To aid in the fundraising the YPC will put together an incredible art and silent auction, opening on June 11 (till June 27th) available at https://onecau.se/_9fp6y1  featuring experiences, artwork and luxury items including an all-inclusive trip to the stunning Impression Isla Mujeres, luxury items from Jimmy Choo, L’AGENCE, Alice + Olivia, a 3 -night stay in a beautiful ocean view room at Round Hill Hotel Jamaica, as well as two custom painted Heller Furniture chairs by artists Ross Pino and Jason Naylor and so much more!

“Our young professionals are the hope for the future. Their passion, purpose, and drive ensure that the legacy of love and the pursuit of a cancer free future lives on. My daughter, Gabrielle would be so proud.” – Denise Rich

FOUNDING CHAIRS of the event include Ayaan Ahmed, Becca Morris, Hugh Barton, Louie Torrellas, and Lydia Maltseva.

CO-CHAIRS for this year’s event are Alana Kramer, Aleksandra Sasha Tikhomirova, Alex Pita, Alex Ulsvgard, Anjali Peddanna, Danielle Rutigliano, Eugenia Bullock, Fer Da Silva, Isabella Sylvester, Jason Naylor, Julia Lindenthal, Julio Galvez, Kayla Rich Kilstock, Kyle Persaud, Lauren Summa, Nancy Moeller, Nicoletta Kolpakov, Ross Pino, Shirin Lotfi, and Vikrant Patel.

The HOST COMMITTEE members are Alexandrea LaFata, Adriana T. Ingenito, Anne Li Caleb Brenes, Christina Lo, Eric Lerner, Gabe Galper, Heather Grabin, Jade Walk, Jagger Walk, Jesse Walk, Juanito Renato, Kemi Areke, Lindsay Karp, and Mareli Maemets.

More About This Year’s Honorees

Kyle Lutnick serves as Executive Vice Chairman of Cantor Fitzgerald, L.P. and has been a Director of Newmark Group, Inc. since February 2025. Most recently Lutnick served as Global Managing Director of Knotel, Inc., Newmark’s flexible office and workspace business and prior was Knotel’s General Manager of UK & EMEA and Vice President of Business Development. Previously, Lutnick was a member of Newmark’s market-leading retail advisory team, where he advised clients in New York City, one of the most dynamic commercial markets in the world.  Lutnick graduated with a Bachelor of Arts in Psychology from Stanford University.

With over 20 years in the beauty industry, Ms. DiNunzio has driven growth and profitability for Fortune 500 and Private Equity-backed companies including L’Oréal, Laura Mercier, and Neutrogena. Currently General Manager of Ultra-Luxury Skincare and Fragrance at Coty USA, she is accelerating the company’s skincare platform. Her previous leadership roles include President of Lashify, where she doubled sales in 12 months, CEO of Dermaflash, and General Manager of North America for Iluminage Beauty, where she led successful turnarounds. Her expertise spans strategic planning, P&L management, marketing, product development, customer insights, sales leadership, and building brands across DTC, Mass, Prestige, Social, and TV Retail channels. Known for cultivating high-performance teams and empowering next-gen leaders through organizations like CEW and Chief, she holds a BA in Biology, an MBA from the University of Virginia, and is a Pew Foundation genetics research grant recipient.

About Gabrielle’s Angel Foundation for Cancer Research

Gabrielle’s Angel Foundation for Cancer Research funds the best and brightest early career scientists whose research focuses on finding less toxic treatments for patients with leukemia, lymphoma, and related blood cancers.  Since its inception in 1996, the Foundation has funded more than $45 million dollars in grants making it one of the largest non-governmental sources of grant support to blood cancer research in the nation. On average, eight-eight cents of every dollar raised directly funds research. For over twenty-five years, the Foundation has honored Gabrielle’s legacy by funding the boldest, most cutting-edge ideas in cancer research.

On Twitter @CureCancerNow

On Facebook & Instagram @GabriellesAngels and @GabriellesYoungAngels

The post Gabrielles Children, The Young Angels Gala, sponsored by Cantor appeared first on Good News!.

Some may know that our multicultural marketing and broadcasting company, Milestone Broadcast Corporation was established in 1985, with the inspiration of working with the Chinese and Asian community. MBC, celebrates our 40 Anniversary as a full service multicultural marketing and broadcasting company, with  to many corporations, i.e., Citibank, Delta Airlines, IBM, Sprint, US Postal, Western Union…who have trusted us to assist them to make friends and do business with over 100 multicultural communities. 

NOTE: You can travel to China with no VISA for 240 hours…also my hotel is $40 and Peking Duck Dinner for 2 is $20 on Westside of Beijing…

 Also, on July 4th will be the 27th Anniversary of our www.youtube.com/goodnewsbroadcast with 7,000 + Shows and www.goodnewsplanet.tv 

WE can help YOU. 

Here is an invitation to the UN, on June 9th, my birthday, hehe…for the International Day of for a Dialogue if it is still open.

Permanent Mission of China:

Celebration of the

International Day for

Dialogue among Civilizations

Here are some Health Stories

LEUKEMIA IS A TYPE OF

CANCER THAT AFFECTS THE

BLOOD OR BONE MARROW.

Rare Liver Disease –

biliary cholangitis

Lastly, if you care about your money, please tune in to WOR 710 Radio on Sunday at 10:30 AM. Here you can listen and call in to Legal Expert and Elder Care Lawyer, 14 Year NYS Representative and Dr. Phil, ET, Good Morning America…Guest Lawyer, Ann-Margaret Carrozza, ESQ. 

Ann is BRILLIANT, AND YOUR MONEY IS BRILLIANT, AND YOU ARE BRILLIANT IF YOU ARE SMART ENOUGH TO PROTECT IT.

Paul Sladkus is Ann’s Co-Host. Email me paul.sladkus1@gmail.com if you want me to ask her a question, or just call in (800-321-0710) and listen; it might be one of the most important programs in you and your family’s life.

Ann-Margaret Carrozza,

Asset Protection Lawyer,

WOR 710 AM

CALL IN Radio

LIVE Every

Sunday at 1030am

STAY WELL

Please support our nonprofit, 501 C 3, Good News Corporation at http://goodnewsplanet.com/peacedayparty/peace-day-donations/

LET’S GROW TOGETHER. GOOD NEWS MOTTO: “All we are is what we are with each other.” Zeal 

With Respect. Love and May Peace Prevail on Earth,  For Information Contact: 

Reverend Paul Sladkus, All Faiths and Spiritual,

Founder, Good News Corporation 501 C 3 212 647 1212 paul.sladkus1@gmail.com  and our Good News and Peace Worldwide Team who make our Peace Day 9/21 happen.

www.pausetheworldforpeace.org,www.goodnewsplanet.TV, www.youtube.com/goodnewsbroadcast

Social Networks: www.Facebook.com/PaulSladkus, LinkedIn Paul Sladkus, Twitter/X Good News to Go, Instagram PausetheWorld

LET’S GROW TOGETHER. GOOD NEWS MOTTO: ALL WE ARE IS WHAT WE ARE WITH EACH OTHER. ZEAL

For more information contact: 

Reverend Paul Sladkus, All Faiths and Spiritual 212 647 1212

New York, NY, Montauk, NY

PS – SPECIAL OPPORTUNITY FOR OUR FRIENDS AND MEMBERS: Looking for a vacation rental, SHORT TERM, in Montauk, this year and or entire summer in 2026, here is our listing https://pausetheworldforpeace.org/2025/04/16/36000-2br-one-of-a-kind-summer-rental-opportunty-historic-montauk-manor-montauk/  call me. Paul 917 687 1790

The post GoodNewsLetter: Beijing, China 40th Anniversary of MBC, 27th of Good News Broadcast, A invitation to the UN and HEALTH Good News appeared first on Good News!.

LEUKEMIA IS A TYPE OF CANCER THAT AFFECTS THE BLOOD OR BONE MARROW. 1 ONE TYPE IS PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID (MY’-uh-loyd) LEUKEMIA.

SOME PATIENTS WITH C-M-L MAY HAVE DIFFICULTY FINDING A TREATMENT THAT’S RIGHT FOR THEM.

ALMOST 15% OF C-M-L PATIENTS DISCONTINUE THEIR TREATMENT IN THE FIRST YEAR DUE TO SIDE EFFECTS, SO HAVING DIFFERENT OPTIONS IS CRITICAL.3-7

HERE TO SHARE HER OWN EXPERIENCE BEING DIAGNOSED WITH PHILADELPHIA CHROMOSOME-POSITIVE C-M-L IN CHRONIC PHASE AND HOW SHE FOUND A TREATMENT THAT WORKED FOR HER, IS TEACHER AND C-M-L PATIENT, JEN. AND HERE TO TALK ABOUT TREATING ADULTS WITH C-M-L, IS DR. JAMES DUGAN (DOO’-guhn.)

HCP Bio: Dr. James Dugan

Dr. James Dugan is a hematology/oncology specialist, and the physician lead for the transplant and cellular therapy department for Novant Health Cancer Institute in Winston-Salem, North Carolina.

Dr. Dugan was drawn to the field of oncology by the opportunity to improve a person’s life during a difficult time. He believes that to properly treat the whole person and not just the disease, physicians need to engage in active conversations with the patient throughout the treatment process. Dr. Dugan approaches medicine and oncology as a partnership between the physician and the patient.

Dr. Dugan is a member of the American Society of Hematology, as well as the American Society for Transplant and Cellular therapy. His membership in these organizations keeps him up-to-date on the latest research and treatment options in the field.

When he is not seeing patients, Dr. Dugan enjoys time with his wife and three daughters. He is an outdoor enthusiast who enjoys skiing, scuba diving, kite surfing, and long-distance running. He is passionate about the shared human experience and loves meeting new people and exploring new ideas and places.

Patient Bio: Jen

In 2014, Jen was diagnosed with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
Prior to her diagnosis, Jen devoted her career to serving others. After dedicating 20 years to running inner-city youth programs, Jen became a social worker, supporting women as they rebuilt their lives after incarceration or experiencing domestic violence.
Jen was actively working as a social worker when she was diagnosed with CML. Unfortunately, her diagnosis required her to step away from her career for a period of time. Working closely with her doctor, she navigated the treatment landscape to find a treatment option that worked for her.
Today, she is a teacher in her rural community, educating K-8 students in a one-room schoolhouse. She is also passionate about sharing her journey and advocating for other adults with CML, helping them access the information and support they need to have meaningful conversations with their doctors and navigate their own patient journeys.

LearnCML.com

The post LEUKEMIA IS A TYPE OF CANCER THAT AFFECTS THE BLOOD OR BONE MARROW. appeared first on Good News!.

A diagnosis of chronic lymphocytic (LIM-foh-SIH-tik) leukemia (C-L-L) can be overwhelming, but advances in cancer research, including targeted therapies, have paved the way for more precise treatments. C-L-L is one of the most common blood cancers in adults, and because its progression varies from person to person, choosing a tailored treatment plan is crucial.

brukinsa.com

Today, we’re joined by Lynne who will share her personal journey with C-L-L, and Dr. Nakhle Saba [Knack-Leigh Sah-bah], director of lymphoid malignancy and CAR T-cell (Car-tee cell )therapy at Our Lady of the Lake Cancer Institute, who will provide insight into the latest treatment approaches and why informed decision-making is so essential for those facing this disease.

BIO’s

Dr. Saba

Dr. Saba earned his medical degree from the Lebanese University in Beirut 2005. He completed his residency in Internal Medicine at East Tennessee State University in Johnson City, TN and Tulane University in New Orleans, LA, and his fellowship in Hematology and Medical Oncology at Tulane University. After fellowship completion in 2011, Dr. Saba joined the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) for an additional fellowship in lymphoid malignancies. His research at the NIH was focused on tumor biology and developing new therapeutic approaches for leukemia and lymphoma. He returned to Tulane in 2014 as Assistant Professor of Medicine, promoted to Associate Professor in 2018, then to Professor in 2024 following a successful career in research, teaching, and treating blood cancers. Dr. Saba’s research focuses on lymphoid malignancies and cell therapy, to identify therapeutic targets and novel drugs for these diseases.

Dr. Saba’s leadership skills are evident by the roles he played at Tulane as chair of the “immune effector cell therapy – IECT”, co-chair of Sarah-Cannon Lymphoma Committee, and President of Louisiana Oncology Society (LOS). Under his direction as president, the LOS passed four bills that were signed into law in Louisiana and are expected to positively impact cancer care in our state. Those bills include the Bone Marrow Donation, Fertility Preservation For Cancer Patients, Right To Prompt Coverage, and Expansion Of Biomarker Testing.

Dr. Saba authored and/or co-authored more than 120 published manuscripts and research abstracts, he presented at regional, national, and international meetings as a researcher and invited speaker. His articles appear in journals like Blood, Leukemia, Cancer Research, The Lancet Haematology, Haematologica, Science Advances, Bone Marrow Transplant and others. Click to access  Dr. Saba’s Bibliography on PubMed  or Dr. Saba’s Articles, Abstracts, and Citations

Dr. Saba was recruited at the Our Lady of the Lake Cancer Institute as Professor of Medicine at LSU Health Sciences Center, and Director of Lymphoma, CLL, and chimeric antigen receptor (CAR)-T. He will be diligently working to expand the lymphoma and CLL research portfolio and bring cutting edge therapies to the region such as CAR-T, the next generation CARs, and be the first to bring the tumor infiltrating lymphocytes (TILs) for solid tumors to Louisiana.

About Lynne

I am a very active, “young” senior citizen whose priorities are my grown children and their partners, my 3-year-old grandson, 20-month-old granddaughter, and my longtime partner. I have a huge passion for all animals, and love doing Pilates, aerobics, Zumba Gold, and weight training. I became a pescetarian about 10 years ago. I was diagnosed with a very specific high-risk subtype of Chronic Lymphocytic Leukemia (CLL) in April 2019, three weeks after the tragic passing of my third child, my 26-year-old daughter. I was so devastated by her death, and now facing an unknown diagnosis, I turned to the Leukemia & Lymphoma Society (LLS) for support. Fast-forwarding to now, I have been on the “Light The Night” Executive Leadership Committee for the Westchester/Fairfield LLS for four years, and my team “Lynne’s Hope” has raised almost $200,000 for the cause, for which I am extremely proud. I am blessed to be under the care of a world-renowned CLL specialist. I want cancer survivors to know there is hope for us to live a long life because of all the constant new medical treatments that are being discovered every day. I have been in treatment for two years for CLL and am doing great! My mantra is, “I will not let Leukemia define me; I will define it!”

The post A diagnosis of chronic lymphocytic (LIM-foh-SIH-tik) leukemia (C-L-L) can be overwhelming, but advances in cancer research… appeared first on Good News!.

BIO:
Dr. Karsh earned his MD from The Chicago Medical School. He completed his General Surgical training at The University of Colorado Health Sciences Center and his Urology Residency at the Brigham and Women’s Hospital/Harvard Medical School.
Dr. Karsh was a co-founder of The Urology Center of Colorado which was recently acquired by Advent Health Urology Denver where he serves as an attending Urologist and Director of Research. He is a certified principal investigator with an experience of more than 275 clinical trials. Dr. Karsh has authored a number of peer-reviewed publications and serves on the editorial boards for “Bladder Cancer.” He is an active member of the AUA, , ASCO, BCAN, SUO,SWOG and the Denver Academy of Surgeons. Dr. Karsh served on the board of SUO from 2010-2020 and served on the bladder cancer subcommittee during that time.

Ferring Pharmaceuticals, Inc.

Website for more information:                           ADSTILADRIN

#cancer #bladdercancer #drkarsh #mike

The post BLADDER CANCER IS THE SIXTH MOST COMMON CANCER IN THIS COUNTRY? appeared first on Good News!.

Discover the latest research and practical tips to boost your well-being and aim for 120 years — with quality and quantity of life.

The post Big News & Live TONIGHT Zoom Event: ComedyCures w/Saranne! appeared first on Good News!.

THIS SERIOUS, RARE, AND MISUNDERSTOOD CANCER HAS A PRIMARY RISK FACTOR THAT IS MORE PREVALENT THAN YOU MIGHT THINK. HUMAN PAPILLOMAVIRUS OR HPV—A COMMON VIRUS TRANSMITTED BY SKIN-TO-SKIN CONTACT—IS THE NUMBER ONE RISK FACTOR FOR ANAL CANCER.^1,2

MARCH IS ANAL CANCER AWARENESS MONTH. JOINING US TO SPEAK ABOUT THE IMPORTANCE OF TALKING OPENLY ABOUT THE RISK FACTORS AND SYMPTOMS OF THIS CANCER THAT CAN BE DIFFICULT TO TALK ABOUT ARE ANAL CANCER SPECIALIST, DR. PAUL ROMESSER [ROME-EH-SIR], AND LILLIAN KREPPEL [LILL-EE-IN KREH-PELL], ANAL CANCER SURVIVOR AND CO-FOUNDER AND EXECUTIVE DIRECTOR OF THE HPV CANCERS ALLIANCE.

BIO- Paul Romesser, MD

Colorectal and Anal Cancer Specialist

Dr. Paul Romesser is a board-certified radiation oncologist specializing in the treatment of colorectal and anal cancer. He is also actively involved in anal cancer clinical trials. Dr. Romesser is passionate about helping patients navigate the complexities of cancer care and create personalized treatment plans tailored to their needs.

BIO-Lillian Kreppel

Co-Founder and Executive Director of HPV Cancers Alliance

Lillian is an anal cancer “thriver,” patient advocate and the Co-Founder and Executive Director of HPV Cancers Alliance, a 501(c)(3) non-profit organization dedicated to raising awareness of human papilloma virus (HPV) and the cancers it can cause. She was diagnosed with HPV-related anal cancer in 2017 and has been a passionate activist and changemaker for the HPV and anal cancer community ever since.

In her own words, “No one should die from HPV – education and self-advocacy can save your life. HPV desperately needs a voice. I AM THAT VOICE!”

The bottom line: Get informed and speak up about risk factors, symptoms, and better care at all stages

Anal cancer can go undetected as it shares many of the same symptoms as common, non-cancer conditions.1 Further, people experiencing symptoms can be embarrassed to discuss them with their doctor and unaware of the key risk factors for anal cancer, which may lead to a delayed diagnosis. Open and honest communication is critical with this cancer, as early diagnosis may help improve outcomes.2

The #1 risk factor for anal cancer is human papillomavirus (HPV), a common virus transmitted by skin-to-skin contact.2,3 Other key facts about HPV include:

Nearly all sexually active people will be infected with HPV at some point in their lives.4
A healthy immune system will rid most HPV infections within two years before they cause precancer cell changes.4
Approximately 90% of anal cancers are associated with HPV infection.5
While anal cancer is rare, its incidence is on the rise.6
Squamous cell carcinoma of the anal canal (SCAC) is the most common type of anal cancer, accounting for about 90% of all anal cancers.7

On Wednesday, March 19, in recognition of Anal Cancer Awareness Month, Lillian Kreppel, Executive Director and Co-Founder of the HPV Cancers Alliance (hpvca.org), and colorectal and anal cancer specialist, Dr. Paul Romesser, is going to discuss their personal and expert perspectives about the condition and the importance of open conversations with healthcare providers at all stages of the journey.

Together, Lillian and Dr. Romesser aim to raise national awareness of anal cancer and its connection to HPV, as well as inspire more open and comfortable communication and better care at all stages. No one is alone in this journey.

#analcancer #cancer

The post **March is Anal Cancer Awareness Month** appeared first on Good News!.

Courtesy: Mirum Pharmaceuticals, Inc

#pspartners #mirum

The post Rare Disease Day is February 28thIT MAY BE AN “INVISIBLE ILLNESS” Yet One Major Symptom Remains Relentless Hear from Former NCAA All-American Hockey Player Who is Now a Hockey Coach appeared first on Good News!.

We are excited to announce a groundbreaking partnership with The Mark Foundation for Cancer Research (MFCR). Together, we are launching a global initiative to fund innovative research projects exploring the complex connection between aging and cancer.

Later this month we will be inviting leading scientists from across the globe to submit novel research proposals that are focused in this field.

Selected projects will receive $500,000 in funding over three years, during which time, SWCRF along with MFCR, plan to invest up to $11 million into specific aging-cancer research.

This significant financial commitment underscores our organization’s shared dedication to advancing pioneering science and tackling cancer’s toughest challenges.

Since, aging is the leading cause of cancer development and progression, as well as poses many treatment challenges, this area of research is crucial to combating the global rise in cancer incidence and improving outcomes for all cancer patients.

These research projects will address critical topics such as:

• Identifying actionable biomarkers that predict aging/cancer risk.
• Understanding how aging impacts tumor growth.
• Exploring the role of the aging immune system in cancer treatment.
• Investigating how metabolism and genetics contribute to cancer development.
• Studying how premature aging increases cancer risk for younger adults.

By supporting this program, SWCRF is further cementing its international leadership in addressing one of the most urgent challenges in cancer prevention and treatment today.

Your continuing support makes this possible. Please consider donating today to help fund this and other vital research programs.

Let’s work together to end cancer in our lifetime.

Warm regards,

Samuel Waxman, MD

Founder and CEO

William T. Sullivan

Executive Director

CLINICAL BREAKTHROUGHS

New Treatment for Liver Cancer Slows Progression and

Improves Survival

A recent study by SWCRF-investigator, Dr. Josep Llovet (Icahn School of Medicine at Mount Sinai), and colleagues has discovered a new treatment approach for unresectable,

non-metastatic hepatocellular carcinoma (HCC)—a form of liver cancer that cannot be surgically removed and has not yet spread to other parts of the body. Around 45,000 cases of HCC are diagnosed yearly in the US and about 1M globally.

According to their research, published in The Lancet (January 2025), combining transarterial chemoembolisation (TACE) with the drugs lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy) significantly improved patient outcomes compared to the placebo group.

Specifically, patients receiving this combination therapy experienced slower tumor progression and a trend towards overall higher survival rates. Additionally, the drug combination was well-tolerated, with manageable side effects, supporting its potential as a viable treatment option in patients with intermediate HCC.

“SWCRF has been instrumental in supporting the development of the HCC program at Mount Sinai since 2004. Their commitment to funding innovative cancer research has allowed us to make these significant strides in understanding and treating this devastating disease. This breakthrough would not have been possible without their continued support”, said Dr Josep M Llovet, Professor of Medicine and Director of the Liver Cancer Program at the Ichan School of Medicine.

This remarkable improvement marks the first clinical breakthrough in treating this challenging and often fatal form of cancer in more than 20 years.

SAVE-THE-DATE

SAVE-THE-DATE

THE WAXMAN LUNCHEON

We’re thrilled to announce an exclusive partnership with Seabourn Cruises.

When you book any Seabourn cruise (excluding World Cruise or Grand Cruise), 10% of your fare will be donated directly to the Samuel Waxman Cancer Research Foundation.

This is your chance to indulge in a luxury cruise experience, while supporting cancer research in a meaningful way.

Select from an array of breathtaking itineraries on eligible voyages through December 25, 2025. Choose from voyages to the Amazon, Arctic, Australia & New Zealand, Asia, the Caribbean, the Mediterranean, and more.

To reserve your next adventure, contact our dedicated Seabourn consultant:

Roseanne Bishop, Personal Cruise Consultant

800.929.4747 Ext. 29398

 RBishop@Seabourn.com

**Offer Code: WAXMANCRI**

Prefer to book online or through your travel agent? Simply provide the same offer codes.

Join us in this extraordinary journey – a chance to explore the world and make a positive impact in the fight against cancer. Book today!

Samuel Waxman Cancer Research Foundation | Website | Telephone 212-867-4502

The post SWCRF and The Mark Foundation Partner to Launch $500,000 Aging and Cancer Research Grants appeared first on Good News!.